The themes Icon is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Clinical trial management
Planning and running studies that test medicines or medical devices, including studies before and after a product reaches the market.
Laboratory testing
Tests samples for drug research, including bioanalytical, biomarker, vaccine and central laboratory testing, as well as testing under good manufacturing practice standards.
Patient and site services
Finding and supporting research sites and helping recruit and retain trial participants, including visits and other services provided in patients’ homes.
Clinical data and technology services
Tools and services for collecting, managing and analyzing clinical trial data and supporting study design and execution.
Functional service provision
Supplying staff or specific research functions to a customer, rather than managing the customer’s entire study.
ICON is a contract research organization (CRO) that carries out clinical research and related work for companies developing medicines and medical devices, as well as government and public-health organizations. It can help plan a study, manage trials from early testing through later stages, recruit patients and run laboratory tests. Customers can hire ICON for a complete study or for particular services.
基于 Icon plc 自己向美国证券交易委员会(SEC)提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
US$194.71-2.8%11月13日 收盘
数据截至2026年9月30日,来自2026年10月27日提交的6-K
ICON sells clinical-trial management, testing and patient-recruitment services to drug, biotechnology and medical-device companies and public-health organizations.
Grade D
价格下方的色带显示每个日期的评级,仅依据当时已公开的文件计算。
显示 Icon plc 评级历史 41 个季度中的 2 个。 其余 39 个可回溯到 2016年10月。